Mike has been Director of Business Development for Rare Diseases at GlaxoSmithKline since December 2010. Prior to his current role, he was a Partner at SR One, Limited or SR One, the venture capital subsidiary of GlaxoSmithKline, since September 2008. Mike joined SR One as an associate in July 2005. While at SR One, he was responsible for many of the firm’s investments and was a member or observer to the Boards of Aileron Therapeutics, CalciMedica, Protez (acquired by Novartis), Synovex, Nupathe (PATH), and Trinity Biosystems. Before joining SR One, Mike was an associate at Frantz Medical Ventures and practiced as an attending physician for 6 years. Mike holds a BA in Biological Sciences from Rutgers University, an MD from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and an MBA from the Weatherhead School of Management at Case Western Reserve University. He completed his residency training at Duke University Medical Center and is an alumnus of the Kauffman Fellows Program.